These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16301926)

  • 41. Schizophrenia and antipsychotic medication--better adherence, better outcomes?
    Staring AB; Van der Gaag M; Mulder CL
    Schizophr Res; 2013 Dec; 151(1-3):296-7. PubMed ID: 24238966
    [No Abstract]   [Full Text] [Related]  

  • 42. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial.
    Gharabawi GM; Greenspan A; Rupnow MF; Kosik-Gonzalez C; Bossie CA; Zhu Y; Kalali AH; Awad AG
    BMC Psychiatry; 2006 Oct; 6():45. PubMed ID: 17054789
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Negative symptoms of schizophrenia and compliance with medication.
    Tattan TM; Creed FH
    Schizophr Bull; 2001; 27(1):149-55. PubMed ID: 11215543
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
    Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
    Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cognitive behaviour therapy in patients with schizophrenia who are not prescribed antipsychotic medication: a case series.
    Christodoulides T; Dudley R; Brown S; Turkington D; Beck AT
    Psychol Psychother; 2008 Jun; 81(Pt 2):199-207. PubMed ID: 18230197
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cognitive-behavioural therapy for refractory psychotic symptoms of schizophrenia resistant to atypical antipsychotic medication. Randomised controlled trial.
    Valmaggia LR; van der Gaag M; Tarrier N; Pijnenborg M; Slooff CJ
    Br J Psychiatry; 2005 Apr; 186():324-30. PubMed ID: 15802690
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interventions to improve antipsychotic medication adherence: review of recent literature.
    Dolder CR; Lacro JP; Leckband S; Jeste DV
    J Clin Psychopharmacol; 2003 Aug; 23(4):389-99. PubMed ID: 12920416
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of Motivational Interviewing on Medication Adherence in Schizophrenia.
    Vanderwaal FM
    Issues Ment Health Nurs; 2015; 36(11):900-4. PubMed ID: 26631862
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Therapeutic alliance, a stake in schizophrenia].
    Charpentier A; Goudemand M; Thomas P
    Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Zuclopenthixol dihydrochloride for schizophrenia.
    Kumar A; Strech D
    Cochrane Database Syst Rev; 2005 Oct; (4):CD005474. PubMed ID: 16235403
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Financial incentives for improving adherence to maintenance treatment in patients with psychotic disorders (Money for Medication): a multicentre, open-label, randomised controlled trial.
    Noordraven EL; Wierdsma AI; Blanken P; Bloemendaal AF; Staring AB; Mulder CL
    Lancet Psychiatry; 2017 Mar; 4(3):199-207. PubMed ID: 28236956
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Partial compliance with antipsychotic medication is common in patients with schizophrenia.
    Rummel-Kluge C; Schuster T; Peters S; Kissling W
    Aust N Z J Psychiatry; 2008 May; 42(5):382-8. PubMed ID: 18473256
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risperidone versus olanzapine for schizophrenia.
    Jayaram MB; Hosalli P
    Cochrane Database Syst Rev; 2005 Apr; (2):CD005237. PubMed ID: 15846745
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication.
    Rettenbacher MA; Hofer A; Eder U; Hummer M; Kemmler G; Weiss EM; Fleischhacker WW
    J Clin Psychiatry; 2004 Sep; 65(9):1211-8. PubMed ID: 15367047
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders.
    Janssen B; Gaebel W; Haerter M; Komaharadi F; Lindel B; Weinmann S
    Psychopharmacology (Berl); 2006 Aug; 187(2):229-36. PubMed ID: 16710714
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Relationships between insight and medication adherence in subjects with psychosis].
    Droulout T; Liraud F; Verdoux H
    Encephale; 2003; 29(5):430-7. PubMed ID: 14615692
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nonadherence to antipsychotic treatment in patients with schizophrenic disorders.
    Svestka J; Bitter I
    Neuro Endocrinol Lett; 2007 Feb; 28 Suppl 1():95-116. PubMed ID: 17262005
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aripiprazole versus other atypical antipsychotics for schizophrenia.
    Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S
    Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Compliance and schizophrenia: the predictive potential of insight into illness, symptoms, and side effects.
    Kao YC; Liu YP
    Compr Psychiatry; 2010; 51(6):557-65. PubMed ID: 20965300
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Subjective well-being under the neuroleptic treatment and its relevance for compliance.
    Naber D; Karow A; Lambert M
    Acta Psychiatr Scand Suppl; 2005; (427):29-34. PubMed ID: 15943008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.